Global service provider Almac and TTP Labtech, a global developer and manufacturer of laboratory equipment, have formed an alliance in the field of fluorescence lifetime (FLT) technology to provide class leading screening performance. This will give customers of either party access to a broad range of biological applications coupled with the next generation of microplate reader technology.

FLT as a reading modality offers a robust, antibody-free, homogeneous assay platform which enables the user to avoid interference from fluorescent compounds within a screening library. Developed utilizing experience in peptide engineering and chemical synthesis and design, Almac’s Flexyte assays harness the power and potential of FLT to provide an efficient and economical platform for screening and profiling. The evolving assay platform offers solutions for many major therapeutic target classes including kinases, proteases, phosphatases, DUB and an increasing number of epigenetic targets.

TTP Labtech’s Ameon system represents the next generation of FLT reader technology. By offering real-time decay curve analysis, the Ameon system provides a revolutionary combination of speed, precision and data quality for FLT assays that can be readily integrated into HTS workflows.

‘The development of the Ameon reader by TTP Labtech has introduced an exciting new dimension to FLT technology and we are pleased that Almac’s Flexyte customers will be able to benefit from this advance in reader technology’ said Dr Stephen Barr, president and managing director of Almac Sciences.

Dr. Wayne Bowen, CSO of TTP Labtech, added, “We are excited by the potential of the Flexyte and Ameon reader combination to deliver robust, cost-effective screening results and enhanced productivity through better discrimination of lead compounds.”